In a phase 2 trial, patients having an urticaria exacerbation who used the spray report better hive and pruritus scores than the placebo group.
Detailed price information for Ars Pharmaceuticals Inc (SPRY-Q) from The Globe and Mail including charting and trades.
Patients at risk for anaphylaxis as well as caregivers of children at risk preferred needle-free epinephrine, according to ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for PALYNZIQ® ...
A bill making its way through the Legislature right now would introduce a new required subject in schools. And that's only the tip of the iceberg.
The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...
Feb 23 (Reuters) - Eli Lilly said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results